agil remain wide moat life
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
spin-out hewlett packard divestitur
electron measur busi
novemb agil focus primarili provid tool
analyz structur properti variou chemic molecul
cell agil one lead provid chromatographi
mass spectrometri tool applic varieti
end market includ healthcar chemic energi food
environment field healthcare-rel applic
market agil gener half
sale
instrument informat fiscal sale
relev custom provid relat servic
consum chromatographi column sampl
prepar tool account rest agil sale
half agil sale recur natur howev even
instrument sale rel sticki end
highli regul
pharmaceut end market agil sale
applic intens time-consum
train requir master scientif analysi agil aim
increas exposur sticki custom relationship
overal think top-tier posit end market innov
market oper on-going cost control help
agil grow revenu midsingl digit compound annual
boost margin overal five-year forecast period
intern growth opportun look solid acquisit activ
continu boost growth prospect well profit
perspect expect agil return margin expans
rest forecast period chines sale
govern initi surround countri food qualiti
infrastructur gener pharmaceut price constrain
margin fiscal
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
origin spun hewlett-packard agil evolv
lead life scienc diagnost firm today agil measur
technolog serv broad base custom three oper
segment life scienc appli tool fiscal sale cross
lab sale consist consum servic relat life
scienc appli tool diagnost genom
half sale gener biopharmaceut chemic
energi end market also support clinic lab environment
forens food academ government-rel organ
compani geograph divers oper
china repres largest countri concentr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil remain wide moat
take fresh look top-tier analyt instrument
provid agil maintain wide
moat rate make uniqu life scienc
diagnost industri comparison cover
compani industri earn narrow moat rate
think agil heavi concentr
sticki end market -- biopharmaceut chemic
energi --
reproduc regulatori factor associ
tool contribut wider moat peer
firm enjoy exemplari stewardship rate well
specif disciplin acquisit record recent
year contribut return invest capit
doubl capit cost set apart industri
also help avoid less attract area within
industri capit alloc busi mix factor
contribut wide moat agil compar
narrow moat acquisit compani
thermo fisher scientif gener lower
roic oper less attract busi mix
opinion agil also appear oper
sharehold give us confid
futur
align
valu moder overvalu agil
share recent trade premium per share
fair valu estim roughli time project earn
water share recent trade premium
per share fair valu estim roughli time
project earn assum grow adjust
earn per share compound annual
next five year howev agil organ growth
prospect primarili margin expans water
need reli share repurchas half
annual bottom-lin growth
rais fair valu estim agil per
share primarili reflect cash flow gener
sinc last valuat updat fair valu estim
impli price/adjust earn multipl approxim
top line incorpor annual growth
next five year includ acquisit activ add
nearli basi point organ growth prospect
end market expect agil organ growth
led biopharmaceut overal growth
expect double-digit biologic-rel growth
consid robust gener demand trend low-singl
digit growth small molecul could remain weak
near term given chines initi lower gener
price constrain demand agil
tool expect low-to-mid-singl digit growth rate
agil appli market assumpt
consid agil rel lower price power
end market regul pharmaceut end
market also demand trend intermedi term
eventu may affect weaker econom
environ certain appli market well budget
constraint academ govern market
bottom line expect adjust earn per share
rise roughli compound annual next
five year sale growth primarili margin
expans share repurchas activ retreat
slightli base rel weak growth base
case scenario assum oper margin rise
nearli expect cost
control effort continu potenti improv
margin primarili control sg line also
expect share repurchas activ account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
basi point growth rate use
base-cas earn assumpt valu
time project earn bull-cas scenario
bear-cas scenario result fair valu
estim model incorpor roughli
annual top-lin growth oper margin
drop mid-teen rise
similar agil margin scenario assum
increas price pressur market share loss
competit addit overal slowdown end
market even
repurchas adjust earn per share grow
compound annual next five year
scenario use base-cas earn assumpt agil
valu time project earn bear case
instrument busi consist primarili chromatographi
ga liquid mass spectrometri test tool
intellectu properti on-going innov creat
intang asset moat sourc regulatori
reproduc factor contribut switch cost end
user moat sourc crucial agil on-going
target market
advantag agil enjoy strong return invest
capit includ goodwil doubl capit
cost calcul
agil offer differenti technolog protect
variou intang asset includ patent copyright
trademark portfolio intellectu properti
innov prowess chosen field keep competitor
technolog sinc even slightli
differenti technic featur caus end user
prefer one tool anoth similar tool agil precis
scientif end market see intang asset around
basi point agil annual earn growth
discount assumpt weight averag
cost capit around
give agil medium uncertainti rate thank
sticki end market result rel steadi
demand trend despit depend one-tim
instrument sale delay weak time
gener economi specif end market
bull-cas scenario result per share fair valu
estim assum greater-than-anticip uptak
firm new product signific price power
quick rebound china scenario expect sale
growth compound annual
base case scenario oper margin rise
bull-cas scenario versu
base-cas scenario think adjust earn per
share grow compound annual
next five year includ share repurchas account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
differenti technolog signific moat sourc
differenti proprieti agil tool affect
perform accuraci speed variou research
project enabl differenti product featur
creat intang asset inform decis use
tool specif applic particularli begin
project order remain relev scientist earli
project phase agil must continu innov
abil innov contribut intang asset
busi well agil signific incent
innov sinc new product contribut posit mix
benefit although enjoy like-for-lik price power
gener
initi choic tool base primarili intang
asset agil benefit substanti switch cost
end market exampl agil
develop
manufactur biopharmaceut
extrem sticki busi end market agil
analyt tool critic compon product
method variou drug specifi directli
molecul regulatori approv applic regul
requir product method throughout drug
life-cycle chang manufactur process
includ qualiti assur qualiti control test
often perform agil tool would requir approv
regul regulatori requir reproduc
concern includ employe train learn curv
creat switch cost biopharmaceut custom
result long potenti benefit period
agil highli regul market brand small
molecul period last year discoveri
patent expir larg molecul biolog
period last even longer due difficult
manufactur process also drug key patent
expir gener manufactur often seek util
product method use brand
manufactur reduc product variabl
adopt gener manufactur creat even
longer benefit period agil specif molecul
see narrow still strong moat around agil
analyt instrument use less regul
research applic repres nearli half
agil sale -- intang asset switch
cost support agil moat end market
well importantli agil lead market ga
chromatographi tool often use less
regul end market agil gener doubl
revenu closest peer ga chromatographi
product believ differenti technolog
strong reput innov capabl creat
intang asset advantag ga chromatographi
long use life around year long
life contribut sustain econom profit
even outsid highli regul biopharmaceut end
market specif custom use tool
agil gener recur consum servic
revenu also believ switch cost persist
due train workflow product concern end
user highli special applic scientist
technician travel learn curv new
instrument test reproduc consist may
suffer end user probabl would need signific
technolog improv induc switch provid
end tool use life overal think intang
asset switch cost advantag associ
highli special analyt instrument creat
stabl market share agil enjoy even
agil diagnost divis repres
sale also advantag intang asset
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chang substanti go forward rel
matur sticki end market see potenti
challeng ahead agil clinic diagnost segment
around sale pit larg foe
roch one end spectrum
innov new entrant end fragment
market see potenti disrupt clinic
diagnost market agil must reli heavili
innov succeed creat uncertainti
around sustain return busi
long run point though think agil
innov chop enough
focu workflow
capabl instrument autom regulatori matter
compet effect market long run
therefor see segment drag agil
moat trend current despit higher potenti disrupt
risk long run
associ differenti test platform
primari moat sourc along switch cost
divis agil tool primarili help clinician
diagnos develop therapeut plan patient
concentr oncolog indic
acquisit dako agil enjoy top-tier posit
anatom patholog market tissue-bas cancer
diagnost make major player top-tier diagnost
firm roch compani
instrument base busi relat consum
sale make attract specialti segment
sophist
time-consum test rel broader diagnost
market agil also oper companion diagnost
tool market make consum test help
physician tailor therapeut option patient
provid sampl prepar tool import next
gener sequenc market overal think
divis strong growth prospect combin intang
asset switch cost associ larg
agil sustain
agil moat trend appear stabl us intang
asset front compani continu innov improv
perform analyt tool well user
interfac innov help agil least
maintain market share initi project decis
made crucial on-going system placement
continu relev industri life scienc
appli market includ relat servic
consum sale also see limit
disrupt risk given regulatori reproduc
train factor creat signific barrier entri
sticki busi overal expect limit
group competitor includ perkin elmer
shimadzu thermo fisher ration
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oagil innov engin cost control effort
display strong growth
margin expans sinc spin electron
measur busi keysight novemb
well-establish leader mani core
familiar agil instrument servic
make market share gain competitor difficult
concern
odu depend one-tim sale
exposur cyclic end market agil
financi result may weaken uncertain time
ochines govern initi food gener
pharmaceut constrain growth fiscal
remain seen initi
affect demand agil tool near
oagil continu increas exposur sticki
acquisit emerg cell analysi field
oagil increas appetit acquisit add
uncertainti around magnitud
econom profit long run
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
agil balanc sheet remain flexibl cash
owe debt end april agil held
billion cash compar billion debt
gross leverag virtual
asset held oversea histor agil sharehold
benefit increas access cash cash
flow result tax reform late prior
 tax reform extern financ necessari
financ mani agil capit alloc prioriti
despit compani gener substanti free cash flow
billion cumul fiscal
sinc tax reform agil reduc debt
billion quarter end juli gross
borrow remain stagnant ever sinc even
firm made tuck-in acquisit return sharehold
go forward though expect agil access extern
financ boost return sharehold includ
repurchas billion avail share
repurchas author april make
acquisit pend billion biotek
acquisit net expect tax benefit refin
outstand debt agil debt matur consist
billion senior unsecur note princip
million due million due million
due million due howev
expect firm remain rel conserv
balanc sheet given histor preced
cyclic end market
give agil medium uncertainti rate thank
sticki end market result rel steadi
demand trend despit depend one-tim
instrument sale delay weak time
gener economi specif end market
half agil busi recur natur
mean half particular experi volatil
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
due macroeconom condit budget constraint
exampl agil chemic energi end market
suffer oil ga price plummet
weak condit agil client delay capit
spend cut agil result end market
fortun agil divers custom base off-set
pressur although firm overal growth
deceler rebound past coupl year
stronger demand trend chemic energi
must innov remain relev end user
establish competitor new entrant introduc better
product develop stronger relationship custom
agil may lose market share well abil extract
price increas futur factor could cut
growth margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
assign agil exemplari mark stewardship unlik
aggress consolid industri
appreci agil select use acquisit
divestitur pend biotek acquisit cell
analysi keysight technolog spin-off
novemb improv asset product build
capabl new market although one could argu
valuat paid somewhat rich highli
select rel aggress peer
help agil consist deliv attract return
invest capit also maintain healthi balanc
sharehold modest dividend opportunist
share repurchas program gener view
appropri given potenti cyclic end
market overal
compens polici align
sharehold perform metric determin
variabl compens contribut
ceo pay fiscal name execut
share stock perform rel peer group
compani
spin-off keysight technolog mike
mcmullen previous presid
chemic analysi segment replac william sullivan
ceo agil earli mcmullen long histori
compani predecessor hewlett-packard
date back think transit top
manag team smooth especi
appreci manag abil consist meet
exceed guidanc sinc spin-off
help strong end market period
firm innov cost control effort exampl
compani top-lin grew adjust
oper profit grew compound annual
fiscal fiscal calcul mcmullen
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
also possess one seat agil board
director koh boon hwee -- privat equiti investor
agil board member sinc former hewlett
packard execut respons primarili asia
pacif region -- serv chairman board sinc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
agil remain wide moat
take fresh look top-tier analyt instrument
provid agil maintain wide
moat rate make uniqu life scienc
diagnost industri comparison cover
compani industri earn narrow moat rate
think agil heavi concentr
sticki end market -- biopharmaceut chemic
energi --
reproduc regulatori factor associ
tool contribut wider moat peer
firm enjoy exemplari stewardship rate well
specif disciplin acquisit record recent
year contribut return invest capit
doubl capit cost set apart industri
also help avoid less attract area within
industri capit alloc busi mix factor
contribut wide moat agil compar
narrow moat acquisit compani
thermo fisher scientif gener lower
roic oper less attract busi mix
opinion agil also appear oper
sharehold give us confid
futur
align
valu moder overvalu agil
share recent trade premium per share
fair valu estim roughli time project earn
water share recent trade premium
per share fair valu estim roughli time
project earn assum grow adjust
earn per share compound annual
next five year howev agil organ growth
prospect primarili margin expans water
need reli share repurchas half
annual bottom-lin growth
drop coverag agil apr
drop coverag agil provid broad
coverag compani global
period adjust coverag accord investor
interest staf expect reiniti coverag
agil next month
place agil review transfer
coverag new analyst expect publish new fair
valu estim second quarter
dont anticip chang fair valu estim
wide-moat agil compani fiscal first-quart
result mostli match expect current
revenu earn forecast previous high-
end manag previou guidanc sit
middl compani increas outlook
includ adjust ep
year howev sinc agil continu post solid result
wouldnt surpris see slight increas
manag year-end goal come quarter
agil continu post impress revenu growth
margin expans although face larg neg
currenc effect compani attain organ growth
quarter basi point adjust oper
margin expans academ govern
well chemic energi segment post littl
growth difficult year-over-year comparison strong
result prior-year period addit growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
food segment declin china regulatori
restructur continu headwind begin
annual draw close growth quarter
led biopharma environment diagnost
custom segment post low-double-digit growth
think agil custom segment
post modest growth underli factor appear stabl
anticip favor growth biopharma
diagnost segment thank healthi demand
agil effort boost presenc higher growth
genom sequenc product offer meanwhil
leverag product mix effici
improv effort sustain compani margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
